Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc (RPRX) – Form 4 insider transaction:
On 31 Jul 2025, director Carole Ho reported receiving 8,558 Class A ordinary shares through two restricted-stock-unit (RSU) grants issued under the 2020 Independent Director Equity Incentive Plan:
- 2,752 RSUs as an initial equity award.
- 5,806 RSUs as a pro-rated annual award.
Both tranches vest 100 % on the earlier of (i) one year from grant or (ii) the next annual shareholders’ meeting. The awards carry a cost basis of $0, reflect routine board compensation, and increase Ho’s direct ownership to 8,558 shares. No shares were sold, no derivatives were involved, and the filing references no Rule 10b5-1 trading plan. The disclosure is informational and does not affect Royalty Pharma’s fundamentals.